The US government is investing heavily in research on the comparative effectiveness of various medical treatments and drugs, dedicating $1.1 billion in stimulus funds and earmarking $286 million in the proposed 2011 budget toward related projects. But many policy experts worry that researchers’ historical reliance on white male subjects could lead to far too generalized recommendations for one treatment over another, which could warp decisions on which therapies should be covered by insurance. (Click here to continue reading)